First National Advisers, LLC Bristol Myers Squibb CO Transaction History

First National Advisers, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $531,501 - $699,732	-13,205 Reduced 70.19%	5,607 $232,000
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $364,408 - $413,168	7,595 Added 67.71%	18,812 $1.02 Million
Q4 2023 Feb 08, 2024	SELL	$48.48 - $57.85 $369,417 - $440,817	-7,620 Reduced 40.45%	11,217 $575,000
Q3 2023 Nov 09, 2023	BUY	$57.89 - $64.73 $697,806 - $780,255	12,054 Added 177.71%	18,837 $1.09 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $19,113 - $21,222	-300 Reduced 4.24%	6,783 $433,000
Q1 2023 May 10, 2023	BUY	$65.71 - $74.53 $87,525 - $99,273	1,332 Added 23.16%	7,083 $490,000
Q4 2022 Feb 09, 2023	BUY	$68.48 - $81.09 $174,555 - $206,698	2,549 Added 79.61%	5,751 $413,000
Q3 2022 Nov 04, 2022	BUY	$0.13 - $76.84 $416 - $246,041	3,202 New	3,202 $228,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of First National Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on First National Advisers, LLC with notifications on news.